Table of Contents
Leukemia Research and Treatment
Volume 2015, Article ID 476805, 9 pages
http://dx.doi.org/10.1155/2015/476805
Clinical Study

Characteristics of Adult T-Cell Leukemia/Lymphoma Patients with Long Survival: Prognostic Significance of Skin Lesions and Possible Beneficial Role of Valproic Acid

1Department of Biological Haematology/Martinique Registry of Haematological Malignancies, Pierre-Zobda Quitman Hospital, University Hospital of Martinique, 97200 Fort-de-France, Martinique
2Martinique Cancer Screening Center, 127 Route de Redoute, 97200 Fort-de-France, Martinique
3Clinical Research and Innovation Unit, Pierre-Zobda Quitman Hospital, University Hospital of Martinique, 97200 Fort-de-France, Martinique
4Department of Internal Medicine, Mangot-Vulcin Hospital, University Hospital of Martinique, 97232 Lamentin, Martinique
5Department of Internal Medicine, Pierre Zobda-Quitman Hospital, University Hospital of Martinique, 97200 Fort-de-France, Martinique

Received 12 March 2015; Revised 21 May 2015; Accepted 28 May 2015

Academic Editor: Christophe Nicot

Copyright © 2015 Plumelle Yves et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

We describe the clinical and biological features of ten patients with a survival superior to ten years (long survival), out of 175 patients diagnosed with Adult T-cell Leukemia/Lymphoma (ATL) in Martinique (1983–2013). There were 5 lymphoma and 5 chronic subtypes. Five of them (3 chronic, 2 lymphoma) had been treated with valproic acid (VA) for neurological disorders developed before or after ATL diagnosis, suggesting a beneficial role for VA as a histone deacetylase inhibitor (HDI) in ATL treatment. Total duration of uninterrupted VA treatment ranged from 8 to 37 years. Overall, the 175 incident ATL cases presented with a median survival of 5.43 months. The five VA-treated (VA+) patients presented with longer survival compared to VA treatment-free patients (VA). For chronic subtypes, survival periods were of 213 months for 3 VA+ patients and of 33 months for 11 VA patients (). For lymphoma subtypes, survival periods were of 144 months for 2 VA+ patients versus 6 months for 49 VA patients (). ATL cases with skin lesions, particularly lymphoma subtypes, had a longer survival (13.96 months) compared to those without skin lesions (6.06 months, ). Eight out of the 10 patients presenting with long survival had skin lesions.